Literature DB >> 18360823

Expression pattern and circulating levels of endostatin in patients with pancreas cancer.

Daniel Ohlund1, Bjarne Ardnor, Mikael Oman, Peter Naredi, Malin Sund.   

Abstract

Endostatin is a potent inhibitor of angiogenesis that is cleaved from the basement membrane protein type XVIII collagen. Expression of endostatin has recently been shown by Western blot analysis of tissue lysates in normal pancreas and pancreas cancer tissue. We show here that the expression pattern of type XVIII collagen/endostatin is shifted from a general basement membrane staining and is mainly located in the vasculature during tumor progression. This shift in type XVIII collagen/endostatin expression pattern coincides with an up-regulation of MMPs involved in endostatin processing in the tumor microenvironment, such as MMP-3, MMP-9 and MMP-13. The circulating levels of endostatin was analyzed in patients with pancreas cancer and compared to that of healthy controls, as well as after surgical treatment or in a group of nonoperable patients after intraperitoneal fluorouracil (5-FU) chemotherapy. The results show that patients with pancreas cancer have increased circulating levels of endostatin and that these levels are normalized after surgery or intraperitoneal chemotherapy. These findings indicate that endostatin could be used as a biomarker for pancreas cancer progression. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18360823     DOI: 10.1002/ijc.23468

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

Review 1.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

2.  Prognostic relevance of collagen XVIII expression in metastatic gastric carcinoma.

Authors:  Kyu Sang Lee; Gyeong Sin Park; Sook Hee Hong; Jae Ho Byun; In Sook Woo; Hae-Myung Jeon; Young Seon Hong
Journal:  Tumour Biol       Date:  2010-04-02

Review 3.  The pancreas cancer microenvironment.

Authors:  Christine Feig; Aarthi Gopinathan; Albrecht Neesse; Derek S Chan; Natalie Cook; David A Tuveson
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

4.  Collagen XVIII mutation in Knobloch syndrome with acute lymphoblastic leukemia.

Authors:  Vinit B Mahajan; Ann Haskins Olney; Penny Garrett; Ajit Chary; Ecaterina Dragan; Gary Lerner; Jeffrey Murray; Alexander G Bassuk
Journal:  Am J Med Genet A       Date:  2010-11       Impact factor: 2.802

5.  Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer.

Authors:  D Ohlund; C Lundin; B Ardnor; M Oman; P Naredi; M Sund
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

Review 6.  Tumor stroma derived biomarkers in cancer.

Authors:  Malin Sund; Raghu Kalluri
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

7.  Basic fibroblast growth factor shows prognostic impact on survival in operable non-small cell lung cancer patients.

Authors:  Ming-Ming Hu; Ying Hu; Guang-Kuo Gao; Yi Han; Guang-Li Shi; Bao-Lan Li
Journal:  Thorac Cancer       Date:  2014-12-23       Impact factor: 3.500

8.  Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer.

Authors:  Andrew R Reynolds
Journal:  Dose Response       Date:  2010-04-23       Impact factor: 2.658

9.  RNA interference-mediated silencing of VEGF and bFGF suppresses endostatin secretion in pancreatic carcinoma cells.

Authors:  Changqing Yan; Chuan Wang; Mei Dong; Sanguang Liu; Cheng Qi; Yupei Zhao
Journal:  Oncol Lett       Date:  2013-01-02       Impact factor: 2.967

10.  Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer.

Authors:  Chi Zhang; Wen-Ying Deng; Ning Li; Su-Xia Luo
Journal:  Chronic Dis Transl Med       Date:  2015-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.